Navigation Links
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Date:12/10/2012

e 2 ACE Study Design
This open-label Phase 2 trial included a total of 333 patients with relapsed or refractory AML. Data from 271 patients were reported here from the "confirmatory" phase of the study.  Data from 62 patients from an "exploratory" phase had been reported earlier.  In the "confirmatory" phase, quizartinib was investigated in two separate cohorts, and each of these cohorts was presented in separate oral sessions this week:

  • Cohort 1: Patients who are 60 years of age or older who are relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first remission of less than 12 months duration or are primary refractory to first-line chemotherapy
  • Cohort 2: Patients who are 18 years of age or older, including patients 60 years of age or older, who are relapsed or refractory after one second-line (salvage) regimen or are relapsed or refractory after HSCT

Quizartinib was administered orally, once-a-day, at a starting dose of 90 mg/day (females) or 135 mg/day (males), in 28-day treatment cycles until disease progression, elective HSCT or unacceptable toxicity that could not be mitigated with dose adjustments.  The co-primary endpoints were CRc (CR + CRp + CRi) and CR.   Additionally, partial response (PR), overall survival (OS), HSCT rates, molecular pharmacodynamic (PD) biomarkers and standard safety assessments were evaluated. 

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia (Abstract #43)
Jorge Cortes, M.D., Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Data through Sept. 28, 2012 (representing at least 10 months of follow-up f
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
3. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
6. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
7. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
8. Xstelos Holdings Announces Dividend
9. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... BROOK, N.Y. , April 21, 2015 /PRNewswire/ ... in health insurance marketplace integration and business operation, ... Entity (WBE) with the Centers of Medicare & ... establish an enrollment channel with access to the ... enrollment of eligible consumers into qualified health insurance ...
(Date:4/21/2015)... 2015 Seattle Children,s announced today that 20 ... trial using genetically reprogrammed T cells to treat relapsed ... by highly sensitive tests designed to detect minute amounts ... complete remission included children with very high tumor burdens ... as infants. "These results are extremely encouraging," ...
(Date:4/21/2015)... April 21, 2015 Legal cannabis ... to grow at a rapid pace over the next ... provide technology services for indoor/outdoor cultivators and new cannabis ... Surna Inc. (OTC: SRNA), Totally Hemp Crazy Inc. (OTC: ... (OTC: BVAP), 22 nd Century Group, Inc. (NYSE: ...
Breaking Medicine Technology:Softheon Confirms Web Broker Entity (WBE) Status with the Centers of Medicare & Medicaid Services (CMS) 2Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 2Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 3New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 2New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 3New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 4New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 5New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 6New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 7
... , , PRINCETON, N.J., Nov. 30 ... will present at the Piper Jaffray 21st Annual Health Care Conference ... may access a live webcast of the presentation at www.covance.com ... please log on 10 minutes early. , Covance, with headquarters in ...
... The Special Committee of Independent Directors of Patheon Inc. ("Patheon" ... its affiliate, JLL Patheon Holdings, LLC (collectively, "JLL"), today announced ... agreement in respect of the pending legal actions between the ... that: , until March 2011, the Board will consist ...
Cached Medicine Technology:Patheon and JLL Partners Announce Litigation Settlement 2Patheon and JLL Partners Announce Litigation Settlement 3
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 21, 2015 ... Review, H1 2015” provides comparative analysis on ... strengthens R&D pipelines by identifying new targets ... products. Complete report with TOC is available ... report also reviews key players involved in ...
(Date:4/21/2015)... Angelo’s FabriClean has recently announced that ... clients that avail the area rug cleaning services. Area ... with hi-tech equipments, making use of the quick drying ... natural, high pressure steam extraction to clean even the ... area rugs made with delicate fabric. , “Good ...
(Date:4/21/2015)... Calif. (PRWEB) April 21, 2015 Information is ... , Kevin Ryan, MD, FACP, empowers patients and their families ... Tumor is the Rumor and Cancer is the Answer" and ... authoritative and informative language to guide patients from diagnosis through ... make patients active participants in their treatment, at home and ...
(Date:4/21/2015)... & New York, NY (PRWEB) April 21, 2015 ... global provider of advanced delivery technologies and development ... today announced the launch of ADVASEPT™ Lock, a ... and efficient delivery of injectable medications. Easily opened, ... a safe, convenient and functional container closure with ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Lyft ... Edition 2 for otolaryngologists, bringing the most advanced ... healthcare community. Otolaryngologists can now experience the ... a trusted source in the industry, Lyft, which ... with leading EHRs. , “Lyft is very excited ...
Breaking Medicine News(10 mins):Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2
... today announced,the release and first shipment of their marine-grade ... chair to oil and,gas platform operators in the Gulf ... platforms will enable the safe and timely evacuation of ... the dual-track MOV in response to the offshore,industry demands ...
... TAMPA, Fla., May 13 A complete review ... of a multi-disciplinary and,collaborative approach to weight loss, ... Clinics(R). The use of several proven,weight management strategies ... offer the greatest likelihood of success., NBC,s ...
... Performance during Sports or Play, CARLSBAD, Calif., May ... and retailer of custom-fitted arch supports and,natural sponge rubber ... of arch supports designed specifically for children ages 6 ... "SportFlex," are now,currently available at participating Good Feet Stores ...
... Israel, May 13 Lumenis Inc., a ... and radiofrequency,devices for surgical, aesthetic, and ophthalmic ... Laser Enucleation of the Prostate (HoLEP),preceptor program ... are interested in learning and performing HoLEP. ...
... 2008 Johnson & Johnson today announced that Professor ... Ravinder N. Maini, FRCP, FMedSci, FRS of the Kennedy ... the recipients of the 2008 Dr. Paul Janssen Award ... world-renowned scientists. , The award salutes the most ...
... Denmark, May 12, Warner Chilcott and LEO ... and Drug Administration (FDA) has approved the,New ... 0.005% and,betamethasone dipropionate 0.064%) Topical Suspension. LEO ... the FDA in July 2007. Taclonex Scalp(R) ...
Cached Medicine News:Health News:Research Converging in Favor of New Approach to U.S. Weight Problem 2Health News:Good Feet Announces New Arch Support Product Line for Children Ages 6 and Older 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research 2Health News:Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 4
... optical collection, inspired by the ... Mademoiselle's heart, from the interlinked ... effect. Combining the purity of ... Strass and other light reflections, ...
... and sunwear, inspired by modern ... style, with long lasting wearability. ... collection include sophistication, elegance and ... clean modern shapes, classic styling ...
... frame mounting technology has redefined rimless collections ... taper at the end of each frame ... of the bushing that mounts within the ... a secure fit is created that far ...
... The new GUCCI DONNA eyewear collection ... house,incorporating, with a vintage yet contemporary feel, ... leader., The new GUCCI UOMO optical and ... is,presented in classic lines with cutting-edge design ...
Medicine Products: